Scarica l'app Stockscreener
12.50
0.40%
0.0391
Precedente Chiudi:
$12.46
Aprire:
$12.49
Volume 24 ore:
544.65K
Relative Volume:
0.36
Capitalizzazione di mercato:
$665.34M
Reddito:
$312.78M
Utile/perdita netta:
$-143.56M
Rapporto P/E:
-4.6465
EPS:
-2.69
Flusso di cassa netto:
$1.22M
1 W Prestazione:
-4.50%
1M Prestazione:
-37.85%
6M Prestazione:
-49.64%
1 anno Prestazione:
-54.69%
Intervallo 1D:
$12.37
$12.76
Intervallo di 1 settimana:
$11.26
$12.76
Portata 52W:
$10.96
$34.84
Caredx Inc Stock (CDNA) Company Profile
Nome
Caredx Inc
Settore
Industria
Telefono
415-287-2300
Indirizzo
8000 MARINA BLVD, BRISBANE, CA
Confronta CDNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CDNA
Caredx Inc
|
12.50 | 626.48M | 312.78M | -143.56M | 1.22M | -2.69 |
|
TMO
Thermo Fisher Scientific Inc
|
485.10 | 174.60B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
208.15 | 143.04B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
661.89 | 52.17B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
119.70 | 32.42B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
189.64 | 30.62B | 15.50B | 1.33B | 2.16B | 7.34 |
Caredx Inc Stock (CDNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-15 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2024-08-28 | Iniziato | Wells Fargo | Underweight |
| 2024-08-19 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2024-05-13 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2024-05-01 | Aggiornamento | Craig Hallum | Hold → Buy |
| 2023-11-09 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2023-08-15 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-05-11 | Downgrade | BTIG Research | Buy → Neutral |
| 2023-03-07 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2023-03-03 | Downgrade | Craig Hallum | Buy → Hold |
| 2023-03-03 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| 2022-04-25 | Iniziato | Stephens | Overweight |
| 2021-07-20 | Ripresa | BTIG Research | Buy |
| 2021-06-03 | Iniziato | Goldman | Buy |
| 2021-02-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-10-30 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-08 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-02 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-05 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-26 | Iniziato | BTIG Research | Buy |
| 2020-06-19 | Reiterato | H.C. Wainwright | Buy |
| 2019-10-01 | Ripresa | Craig Hallum | Buy |
| 2019-05-09 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2019-02-15 | Iniziato | Jefferies | Buy |
| 2018-10-23 | Ripresa | Raymond James | Strong Buy |
| 2018-09-18 | Reiterato | H.C. Wainwright | Neutral |
| 2017-11-27 | Iniziato | H.C. Wainwright | Buy |
| 2016-06-14 | Reiterato | Mizuho | Buy |
| 2015-09-29 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2015-09-25 | Iniziato | Craig Hallum | Buy |
| 2015-03-18 | Reiterato | Mizuho | Buy |
Mostra tutto
Caredx Inc Borsa (CDNA) Ultime notizie
CareDx stock price target lowered to $22 at BTIG on Medicare reimbursement concerns - Investing.com
CareDx's Q2 2025 Earnings: Unpacking Contradictions in EPIC Launch, Legal Settlements, and Volume Growth - AInvest
CareDx (CDNA): Analyst Lowers Price Target, Maintains Rating | C - GuruFocus
CareDx (CDNA) Price Target Cut to $14.00, Analyst Maintains 'Equal-Weight' Rating - AInvest
CareDx Reports Strong Growth in Testing Services - MSN
CareDx Inc. Reports Strong Growth Amid Challenges - The Globe and Mail
CareDx, Inc (NASDAQ:CDNA) Q2 2025 Earnings Call Transcript - Insider Monkey
CareDx Q2 2025 slides: 14% revenue growth despite analyst miss, EBITDA surges - Investing.com
How CareDx Inc stock performs during market volatility300% Return Stock Forecast - classian.co.kr
CareDx Publishes KOAR Study In American Journal of Transplantation, Showcasing AlloSure Dd-cfDNA For Enhanced Kidney Rejection Detection And Biopsy Guidance - 富途牛牛
CareDx secretary Novack sells $34,380 in shares - Investing.com
CareDx secretary Novack sells $34,380 in shares By Investing.com - Investing.com India
CareDx Appoints New CFO Amid Financial Growth - MSN
CareDx Faces Financial Challenges Amid Mixed Signals and Policy Uncertainties - TipRanks
CareDx 2025 Q2 Earnings EPS Beats Expectations, Net Loss Widens - AInvest
CareDx narrows 2025 revenue guidance to $367M-$373M as kidney surveillance protocols expand - MSN
CareDx Names Nathan Smith as Chief Financial Officer - MarketScreener
CareDx (CDNA) EPS Beats Sales Gain 14% - sharewise.com
Earnings call transcript: CareDx Q2 2025 misses revenue forecasts By Investing.com - Investing.com South Africa
Earnings call transcript: CareDx Q2 2025 misses revenue forecasts - Investing.com
CareDx Q2 2025 Earnings: EPS of -$0.10 Meets Estimates, Revenue of $90.5 Million Slightly Misses Expectations - AInvest
CareDx Publishes Landmark KOAR Study on AlloSure Efficacy in Kidney Transplant Surveillance in American Journal of Transplantation. - AInvest
CareDx Announces Appointment of Nathan Smith as Chief Financial Officer - BioSpace
CareDx narrows 2025 revenue guidance to $367M-$373M as kidney surveillance protocols expand. - AInvest
CareDx Names Nathan Smith as New CFO - AInvest
Here's What Key Metrics Tell Us About CareDx (CDNA) Q2 Earnings - Yahoo Finance
CareDx (CDNA) Lags Q2 Earnings and Revenue Estimates - Nasdaq
CareDx: Q2 Earnings Snapshot - San Antonio Express-News
CareDx Inc. Faces Q2 Loss with Revenue Below ExpectationsNews and Statistics - IndexBox
CareDx's Strategic Leadership Shift: How CFO Nathan Smith's Appointment Signals a New Era of Growth - AInvest
Caredx Inc earnings beat by $0.20, revenue fell short of estimates - Investing.com South Africa
CareDx narrows FY25 revenue view to $367M-$373M from $365M-$375M - TipRanks
CareDx Reports Q2 Non-GAAP EPS of $0.10, Misses Estimates by $0.02, Revenue Down 6.1% Y/Y - AInvest
CareDx Announces Second Quarter 2025 Financial Results - Business Wire
CareDx Announces Landmark KOAR Study Published in the American Journal of Transplantation - Lelezard
AlloSure kidney transplant test shows strong predictive value for rejection By Investing.com - Investing.com Nigeria
Pinnacle West Q2 Earnings In Line With Estimates, Revenues Rise Y/Y - The Globe and Mail
CareDx ($CDNA) Is Paying a $20.25M Settlement to Investors — Here’s How to Get Your Share - TradingView
What are the technical indicators suggesting about CareDx IncFree Stock Market Return Analysis - Jammu Links News
What are the latest earnings results for CareDx IncGet alerts on high-potential stock breakouts - Jammu Links News
When is CareDx Inc stock expected to show significant growthStrong return on investment - Jammu Links News
Does CareDx Inc stock perform well during market downturnsDiscover dynamic stocks ready to soar - Jammu Links News
How does CareDx Inc compare to its industry peersAchieve consistent profits with disciplined trading - Jammu Links News
Is CareDx Inc stock overvalued or undervaluedExceptional portfolio growth - Jammu Links News
Should I hold or sell CareDx Inc stock in 2025Invest smarter with advanced market data - Jammu Links News
Why is CareDx Inc stock attracting strong analyst attentionStrongest growth potential - Jammu Links News
How volatile is CareDx Inc stock compared to the marketMaximize your returns with expert insights - Jammu Links News
What analysts say about CareDx Inc stockMaximize gains with data-driven trading alerts - Jammu Links News
What is the dividend policy of CareDx Inc stockFree Stock Market Return Analysis - Jammu Links News
What institutional investors are buying CareDx Inc stockTremendous financial leverage - Jammu Links News
Caredx Inc Azioni (CDNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.66%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):